Bluebird Bio is reducing expenses and laying off nearly a third of its employees to preserve cash ahead of two pivotal, gene therapy approval decisions expected later this year, the company said Tuesday.
The restructuring, which aims to save $160 million over the next two years, comes one month after Bluebird warned investors there was “substantial doubt” about its ability to remain solvent beyond this year.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
